Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy for which there is still no effective therapy. In order to identify genetic alterations useful for a new treatment design, we used whole-exome sequencing to analyze 14 BPDCN patients and the patient-...

Descripción completa

Detalles Bibliográficos
Autores principales: Sapienza, Maria Rosaria, Abate, Francesco, Melle, Federica, Orecchioni, Stefania, Fuligni, Fabio, Etebari, Maryam, Tabanelli, Valentina, Laginestra, Maria Antonella, Pileri, Alessandro, Motta, Giovanna, Rossi, Maura, Agostinelli, Claudio, Sabattini, Elena, Pimpinelli, Nicola, Truni, Mauro, Falini, Brunangelo, Cerroni, Lorenzo, Talarico, Giovanna, Piccioni, Rossana, Amente, Stefano, Indio, Valentina, Tarantino, Giuseppe, Brundu, Francesco, Paulli, Marco, Berti, Emilio, Facchetti, Fabio, Dellino, Gaetano Ivan, Bertolini, Francesco, Tripodo, Claudio, Rabadan, Raul, Pileri, Stefano A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442957/
https://www.ncbi.nlm.nih.gov/pubmed/30381297
http://dx.doi.org/10.3324/haematol.2018.202093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442957/
https://www.ncbi.nlm.nih.gov/pubmed/30381297
http://dx.doi.org/10.3324/haematol.2018.202093

Ejemplares similares